The content on this site is intended for healthcare professionals only
Dr Balar speaks with ecancertv at ESMO 2016 about the outcomes of patients receiving immune checkpoint therapy as a first line treatment against metastatic urothelial cancer.
You can read the news coverage of this story here.
These results advance on those of the IMvigor210 trial, described by Dr Balar at ASCO 2016.
Checkpoint therapy for metastatic urothelial cancer was also discussed by Dr Matthew Galsky.